2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P2990
    Enteropeptidase 9014-74-8
    Enteropeptidase (TMPRSS15), a type II transmembrane serine protease and a physiological activator of trypsinogen. Enteropeptidase is associated with the brush border membrane (BBM) of the enterocytes in the upper small intestine. Trypsinogen is the primary substrate for Enteropeptidase. Enteropeptidase is involved in digestion in humans and animals.
    Enteropeptidase
  • HY-P3018
    Uridine-5'-diphosphoglucose pyrophosphorylase 9026-22-6
    Uridine-5'-diphosphoglucose pyrophosphorylase is involved in the catalysis of UDP-glucose synthesis. Uridine-5'-diphosphoglucose pyrophosphorylase can be used to determine the concentration of pyrophosphate in urine.
    Uridine-5'-diphosphoglucose pyrophosphorylase
  • HY-P3121
    Caprooyl-tetrapeptide-3 triacetate 1012317-71-3 98.46%
    Caprooyl-tetrapeptide-3 acetate is used for fine lines and wrinkle reduction. Caprooyl-tetrapeptide-3 acetate stimulates the expression of collagen VII and laminin-5 in a model of corticoid-induced skin ageing.
    Caprooyl-tetrapeptide-3 triacetate
  • HY-P3282
    MM 419447 1092457-78-7 98.62%
    MM 419447, a linaclotide metabolite, is a guanylate cyclase-C agonist. MM 419447 has the potential for the research of the irritable bowel syndrome with constipation (IBS-C).
    MM 419447
  • HY-P3455
    Ac-SVVVRT-NH2 1401804-69-0 98.68%
    Ac-SVVVRT-NH2 is a PGC-1α modulator that modulates the activity of the human PGC-1α promoter (114%). Ac-SVVVRT-NH2 increases PGC-1α mRNA (125%) and accumulation of intracellular lipids (128%) in subcutaneous human adipocytes. Ac-SVVVRT-NH2 can be used in the research of diseases which is modulated by PGC-1α.
    Ac-SVVVRT-NH2
  • HY-P5251
    Oligopeptide-68 1206525-47-4 98.56%
    Oligopeptide-68 is a bioactive peptide with anti-aging effect and has been reported used as a cosmetic ingredient.
    Oligopeptide-68
  • HY-Y0241
    2-Cyanopyrimidine 14080-23-0
    2-Cyanopyrimidine is a potent and non-selective cysteine protease cathepsin K inhibitor with an IC50 of 170 nM. 2-Cyanopyrimidine is used for osteoporos.
    2-Cyanopyrimidine
  • HY-Y0785
    Glyoxal (40% w/w in water) 107-22-2
    Glyoxal is a cytotoxic α-oxoaldehyde. Glyoxal induces cell damage and promotes protein glycation to form advanced glycation end-products (AGEs). Glyoxal is promising for research of oxidative stress-related diseases (such as atherosclerosis, cataract, Alzheimer's disease), and the formation of calcium oxalate kidney stones.
    Glyoxal (40% w/w in water)
  • HY-Y1297
    Oxalic acid dihydrate 6153-56-6
    Oxalic acid dihydrate is an endogenous metabolite.
    Oxalic acid dihydrate
  • HY-100303
    FR194738 free base 204067-45-8 99.84%
    FR194738 free base is a squalene epoxidase inhibitor. FR194738 inhibits squalene epoxidase activity in HepG2 cell homogenates with an IC50 of 9.8 nM.
    FR194738 free base
  • HY-100779
    Rimacalib 215174-50-8 99.14%
    Rimacalib (SMP 114) is a Ca2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor, with IC50s of ~1 μM for CaMKIIα to ~30 μM for CaMKIIγ.
    Rimacalib
  • HY-100935
    Cimaterol 54239-37-1 99.13%
    Cimaterol (CL 263780) is a β-adrenergic agonist on energy metabolism in ob/ob mice. The Kd for Cimaterol binding to the L6 β-receptor is 26 nM which is compatible with its EC50 for the stimulation of protein synthesis (approx 5 nM).
    Cimaterol
  • HY-102052
    DCEBIO 60563-36-2 99.25%
    DCEBIO is a small/medium conductance calcium-activated potassium (SKCa/IKCa) channel opener and primary neuron signal blocker. It hyperpolarizes the membrane potential of C2C12 myoblasts by activating IKCa channels, thereby promoting myogenic differentiation. The specific biological activity of DCEBIO is manifested in increased myotube formation, enhanced myosin heavy chain II protein levels and myogenin mRNA levels. DCEBIO can be applied in the field of muscle research, especially in muscle-related degenerative diseases such as sarcopenia.
    DCEBIO
  • HY-10285A
    Saxagliptin hydrate 945667-22-1 ≥99.0%
    Saxagliptin hydrate (BMS-477118 hydrate) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin hydrate has the peotential for type 2 diabetes mellitus research.
    Saxagliptin hydrate
  • HY-103281
    Litorin 55749-97-8 99.61%
    Litorin, an amphibian bombesin peptide derivative, is an bombesin receptor agonist. Litorin stimulates the contraction of smooth muscle, stimulates gastrin, gastric acid, and pancreatic secretion, and suppresses the nutriment in vivo.
    Litorin
  • HY-103566
    LY456236 338736-46-2 ≥99.0%
    LY456236 is a selective, non-competitive and orally active antagonist of glutamate receptor 1 (mGlu1), which can inhibit phosphatidylinositol hydrolysis with an IC50 of 0.145 μM. LY456236 can also inhibit EGFR, with an IC50 of 0.918 μM. LY456236 blocks cell proliferation by inhibiting the MAPK pathway, reversing the anti-apoptotic effect of DHPG (HY-12598A). LY456236 can be used in epilepsy research.
    LY456236
  • HY-10457A
    Velusetrag hydrochloride 866933-51-9 98.95%
    Velusetrag (TD-5108) hydrochloride is an orally active, potent and selective agonist of serotonin 5-HT4 receptor (5-HT4R), with a pKi of 7.7. Velusetrag hydrochloride exhibits no affinity (Ki>10 μM) for 5-HT2A and 5-HT2B receptors. Velusetrag hydrochloride can be used for the research of gastrointestinal diseases and Parkinson's disease.
    Velusetrag hydrochloride
  • HY-106198
    Lidorestat 245116-90-9 99.50%
    Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation.
    Lidorestat
  • HY-107535
    AS1269574 330981-72-1 99.84%
    AS1269574 is a potent, orally available GPR119 agonist, with an EC50 of 2.5 μM in HEK293 cells expressing human GPR119. AS1269574 activates TRPA1 cation channels to stimulate glucagon-like peptide-1 (GLP-1) secretion. AS1269574 specifically induces glucose-dependent insulin secretion from pancreatic β-cells only under high-glucose conditions. AS1269574 has the potential for the research of type 2 diabetes.
    AS1269574
  • HY-107651
    VU 0365114 1208222-39-2 99.41%
    VU 0365114 is a selective mAChR M5 positive allosteric modulator, with an EC50 of 2.7 μM, and >30 μM for M1, M2, M3 and M4 receptors. VU 0365114 increases insulin secretion stimulated by ACh in human β-cells.
    VU 0365114
Cat. No. Product Name / Synonyms Application Reactivity